* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
None
What’s baking in the oven?
Market Movers:***
14 January: GlobalData (DATA.L), the data, insight, and technology Company expects to submit its application to move to the Main Market from AIM and to take place on 5 March.
Banquet Buffet****
Delta Gold Technologies 31.0p £18.29m (AQSE:DGQ)
The technology Company developing intellectual property (IP) in the quantum computing sector announced a Research Sponsorship and exclusive Technology Licensing Agreement with Penn State University in Pennsylvania, USA. Penn State's recent published work includes structures and methods for quantum computing using gold, which aligns closely with Delta's research at the University of Toronto. The Agreement forms part of Delta's long-term strategy to build a global centre of excellence and a world-class portfolio in quantum materials research across leading universities. Delta Gold will sponsor a first year research programme estimated to be up to USD $997,142 which will be paid to Penn State on a cost reimbursement basis. The research will extend existing work on gold-based quantum technologies with the aim of generating valuable IP. The total cost reimbursable contract is for up to USD $2,991,426 over three years. Delta will pay Penn State a running royalty of one percent on Net Sales of licensed products once cumulative Net Sales exceed $20m.
Genflow Biosciences 2.03p £9.38m (GENF.L)
The European-based biotechnology Company focused on the development of gene therapies for age-related diseases announced positive preliminary interim results from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy in aged dogs. The randomised, blinded study, conducted by an independent contract research organisation, enrolled 24 beagle dogs aged over 10 years who were allocated to four groups: two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 cohort, and a control group. All treatment groups demonstrated superior survival compared to the control group during the dosing period. No adverse events were observed, and all treatment modalities exhibited a favourable safety and tolerability profile suitable for use in aged companion animals.
Helium One Global Ltd 0.49p £43.07m (HE1.L)
The primary helium explorer in Tanzania with a 50% working interest in the Galactica-Pegasus helium development project in Colorado, USA provides an update following the Blue Star Helium announcement issued today regarding the Galactica Project. The Pinon Canyon Plant is scheduled for integrated plant operations next week, with the amine unit operational in removing CO2 from the input gas stream. Sales arrangements have been made for spot sales of helium, and discussions regarding long-term contracts with both helium and CO2 off-takers progressing well.
Inspiration Healthcare Group 18.50p £15.47m (IHC.L)
The medical technology Company pioneering best-in-class, specialist neonatal intensive care medical devices updates on Trading for the FY January 2026. Revenues in H2 increased 10.3% to £23.5m and the Company has reported 24% FY growth to £47.5m. There is a new multi-year purchasing agreement signed with one of the largest hospital networks in the US, so sales momentum is expected to continue into FY27. The adjusted EBITDA is set to be in line with market expectations for £2.8m. The net debt was reduced by 39% to £5.1m having achieved significant reductions in inventory and receivables under the 'Back to Basics' strategy. The solid pipeline of opportunities gives the CEO confidence in the 2027’s outcome.
IXICO 10.50p £9.50m (IXI.L)
The Company engaging in neuroscience imaging and biomarker analytics using its AI-driven platform to help advance drug development in neurological disorders today announced the extension of an existing contract with an international pharmaceutical company following the continued progress of a Phase 2 clinical trial in Huntington's Disease. The contract extension is worth an additional c.£1.5m in revenues to IXICO over the next three years.
Ondo InsurTech 17.25p £26.22m (ONDO.L)
The provider of claims prevention technology for home insurers announced that it has signed its first joint insurance customer via its strategic partnership with vipHomeLink Holdings, Inc. The new insurance partner, The Co-operative Insurance Companies, will launch the LeakBot water loss prevention program to their insured homeowners across Vermont and New Hampshire, with implementation currently underway.
Physiomics 0.50p £1.52m (PYC.L)*
The mathematical modelling, data science and biostatistics Company supporting the development of new therapeutics and personalised medicine solutions has announced a contract award with a new biopharmaceutical client headquartered in South Korea. This new project is with a South Korean clinical stage biopharmaceutical company focused on the development of next-generation antibody drug conjugate and Immuno-oncology therapeutic for the treatment of cancer. Under the terms of the contract, Physiomics will use PK/PD modelling and simulation techniques to support dosing decisions for one of the client's clinical stage assets. The project, valued at up to £66,600, will commence immediately with completion anticipated within the next two months.
Sancus Lending Group Ltd 1.20p £9.77m (LEND.L)
The finance provider announced it has entered into definitive legal agreements to increase the size, and extend the maturity, of its existing credit facility with Pollen Street Capital, following a strong year of lending growth across its UK and Ireland businesses. Under the revised terms, the size of the facility has been increased from £200m to £300m, with the tenor extended such that it will now mature no earlier than 11th February 2031, providing at least five years of committed funding from the date of the agreed terms.
Thruvision Group 0.98p £4.26m (THRU.L)
The provider of walk-through security technology announces that it has secured its first UK subscription sales under its "Screening as a Service" model. In November 2025, the Company launched "Screening as a Service", a flexible subscription-based offering that enables customers to access Thruvision's advanced screening solution, including support and training, for a fixed monthly fee. The initiative was designed to remove the need for significant upfront investment enabling organisations across the UK to deploy Thruvision's proven security solutions quickly and cost-effectively. These initial orders mark a significant milestone in the roll-out of the subscription model and underscores growing customer demand for more flexible procurement solutions.
TPXimpact Holdings 34.50p £26.65m (TPX.L)
The technology-enabled services Company focused on people-powered digital transformation announced that it has been selected as the successful bidder for a £39m, 4-year contract with the Department for Environment, Food & Rural Affairs (DEFRA). Following a competitive tender process, the Company has been awarded the Service Type 3 - Product Development lot under DEFRA's new Digital, Data and Technology "Capability as a Service" resourcing model. This strategic award builds upon TPXimpact's existing position as an incumbent provider for User-Centred Design roles within the department.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
